Major shareholder notification
In accordance with Section 29 of the Securities Trading Act, Novo
Nordisk hereby reports that The Capital Group Companies on 29 August
2008 informed Novo Nordisk that the voting rights attributable to
their shareholding in Novo Nordisk are now below the threshold of 5%
The Capital Group Companies now holds 63,668,444 B shares of DKK 1
equal to 10.04% of the total share capital in Novo Nordisk,
corresponding to 3.98% of the voting rights.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,300
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Elin K Hansen Mads Veggerby Lausten
Tel (direct): (+45) 4442 3450 Tel (direct): (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel (direct): (+45) 4442 4765 hrmm@novonordisk.com
In North America:
Sean Clements
Tel (direct): (+1) 609 514 8316
secl@novonordisk.com
Company Announcement no 55 / 2008